Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
myristoylated human defensin 5
- Development stage
- Preclinical
- Lead developer
- Zhejiang University
- Modality
- Peptides, Nanoparticles → Drug Delivery Systems
- Administration
- Intraperitoneal, Intravenous, Topical
01
Overview
Myristoylated human defensin 5 (HD5-myr) is a C-terminally myristoylated, self-assembling antimicrobial peptide (AMP) derived from human α-defensin 5 (HD5). Developed by researchers at Zhejiang University and collaborating institutions, HD5-myr self-assembles into nanostructures (nanobiotics) that exhibit enhanced broad-spectrum bactericidal activity compared to unmodified HD5. It functions by disrupting bacterial cell walls and membranes, and by directly binding and neutralizing bacterial endotoxins (lipopolysaccharides, LPS). The resulting HD5-myr/LPS complexes are rapidly cleared by macrophages via F-actin-dependent phagocytosis, which upregulates acyloxyacyl hydrolase (AOAH) expression to facilitate intracellular LPS degradation []. HD5-myr is under preclinical investigation for the treatment of sepsis, bacterial infections (including MRSA skin infections), and as a component of antimicrobial wound dressings.
- Other names
- C-terminally myristoylated human alpha-defensin 5myristoylated human alpha-defensin 5
Beyond the preview
Go deeper on myristoylated human defensin 5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on myristoylated human defensin 5.